Introduction
Ezra is a New York-based healthcare company founded in 2018 by Emi Gal, who serves as co-founder and chief executive officer per Ezra’s mission and leadership page. Ezra provides MRI-based cancer and condition screening enhanced by artificial intelligence across imaging acquisition, analysis, and reporting — positioning early detection as a proactive consumer health service rather than solely a symptomatic diagnostic pathway.
Gal, a software engineer and serial entrepreneur previously behind Brainient (acquired by Teads), built Ezra to make full-body and regional MRI screening faster, more affordable, and more accessible through outpatient imaging partnerships including RadNet locations across U.S. metropolitan markets. Ezra’s membership pricing and HSA/FSA eligibility messaging target consumers willing to pay out-of-pocket for screening outside traditional insurance preventive schedules.
What the company does
Ezra operates screening programs that use MRI protocols to assess up to thirteen organ regions in full-body scans, detecting potential cancers and other actionable findings such as aneurysms or fatty liver changes. AI spans the workflow: Ezra Flash improves image quality and reduces scan time; Ezra Prostate AI supports prostate MRI reads; Ezra Reporter AI structures radiology reports for member-friendly interpretation. Members book scans online, complete medical questionnaires, receive imaging at partner facilities, and obtain reports with clinical follow-up guidance.
Ezra’s membership tiers and regional scan SKUs let consumers choose full-body versus organ-specific screening depth — a product structure Gal has iterated as Flash AI shortens acquisition times and lowers per-scan operational cost at partner imaging centers.
Who it serves
Ezra serves consumers willing to pay out-of-pocket or through membership plans for proactive screening — a segment distinct from insurance-driven diagnostic imaging ordered after symptoms. Employer and wellness partnerships extend reach; Ezra cites helping a meaningful share of members identify potential cancer through scans in its FDA clearance blog post. Gal frames the mission as detecting cancer early for everyone globally, with U.S. metro expansion as a step toward broader access rather than the endpoint.
Company background
Gal founded Ezra in 2018 after observing how late-stage cancer diagnoses dominate survival statistics. The company pioneered consumer full-body MRI offerings in the United States, expanding from New York and New Jersey into California, Las Vegas, and additional markets through RadNet and other imaging partners described in Ezra blog materials. Ezra received prior FDA clearances for neuro-focused Ezra Flash capabilities before the February 2025 clearance expanded abdomen and pelvis enhancement — a regulatory milestone Gal tied to a future fifteen-minute, five-hundred-dollar scan target in official blog commentary.
Gal’s ad-tech background informed Ezra’s consumer marketing and membership pricing experiments — applying growth metrics from software to healthcare services while maintaining radiology medical director oversight for clinical sign-off.
Product and AI capabilities
Ezra Flash AI uses deep learning to reduce MRI noise while preserving diagnostic information across neuro, abdomen, and pelvis regions — enabling shorter protocols without sacrificing interpretability, per Ezra’s FDA clearance announcement. Integrating AI across capture, organ-specific analysis, and reporting distinguishes Ezra from imaging centers offering raw MRI without structured AI QA. Gal stated Ezra was among the first companies globally to integrate AI across the entire cancer screening process, though buyers should evaluate clinical utility and false-positive management policies independently of marketing claims.
Shorter scan durations improve partner imaging center utilization — a business metric Ezra must optimize to pursue Gal’s stated fifteen-minute, five-hundred-dollar scan goal referenced in the Flash clearance blog post.
Key developments
2018: Ezra founded in New York by Emi Gal. February 20, 2025: FDA 510(k) clearance for expanded Ezra Flash AI (ezra.com blog, official source). 2026: Ezra continued U.S. location expansion; Gal referenced operating across dozens of cities in clearance follow-on communications on Ezra blog.
Ezra’s Function membership partnership and multi-tier scan SKUs listed on its consumer site reflect ongoing pricing experiments as Gal pursues lower-cost protocols enabled by Flash AI efficiency gains.
Why it matters
Ezra matters because MRI screening sits at the controversial edge of preventive health — high sensitivity, cost, and interpretability challenges — and AI is Ezra’s bet to compress scan time and price sufficiently for broader adoption. FDA clearance for expanded Flash capabilities is a concrete regulatory milestone, not merely a research preprint. Ezra complements Brel’s medical imaging coverage alongside oncology detection AI vendors like Lunit but targets consumer screening workflows rather than hospital radiology departments.
Members considering Ezra scans should understand follow-up pathways for incidental findings — screening value depends on coordinated referral workflows, not detection alone.
Sector context
Ezra belongs in Brel’s AI in healthcare coverage under medical imaging and consumer preventive screening, distinct from blood-based multi-cancer tests from companies such as Freenome. Readers should separate FDA software clearance for image enhancement from screening program clinical guidelines or payer coverage — three different adoption gates.
Consumer MRI screening occupies a regulatory and ethical debate distinct from hospital radiology AI — Ezra profiles should be read alongside professional society guidance on opportunistic screening, not only vendor performance claims.
Sources and references
Ezra Flash FDA clearance blog post (February 20, 2025) and Mission leadership page.
- Ezra — Ezra Flash FDA 510(k) clearance (ezra.com, February 20, 2025)
- Ezra — Mission / Emi Gal (ezra.com)
Reviewed July 10, 2026. Emi Gal is founder and CEO.